Aim: In this study, it was aimed to determine the reproducing agents and the antibiotic susceptibility of the agents in a total of 89 urine samples cultured in Ankara Training and Research Hospital, Infectious Diseases and Clinical Microbiology laboratory during the 6-month period between 2021-2022. Material and Method: While growth was detected in urine culture in 68 (76%) of 89 urine samples taken in the study, no growth was found in 21 (24%) of them. Antibiotic susceptibility was studied on Mueller-Hinton agar by the disc diffusion method in isolates with growth in urine culture. Results: Reproducing factors are in order of frequency; 25 E. coli, 17 extended-spectrum beta-lactamase (ESBL) positive E. coli, 10 Klebsiella pneumoniae, 3 Pseudomonas aeruginosa, 3 Proteus mirabilis, 3 Enterococcus faecalis, 1 Enterobacter cloacae, 1 Candida krusei, 1 Staphylococcus aureus, 1 patient E. coli and Proteus species were determined. Resistance rates in E. coli strains isolated from urine culture; 20% (4/20) for ciprofloxacin, 5% (1/19) for nitrofurantoin, 9.5% (2/21) for trimethoprim/ sulfamethoxazole (TMP/SMZ). No resistance was found to fosfomycin 0% (0/19) and to carbapenems (imipenem, meropenem, and ertapenem) (0/21). The resistance rates in ESBL positive E. coli strains are; 100% (13/13) for ciprofloxacin, 7% (1/14) for nitrofurantoin, 12.5% (1/8) for fosfomycin, 26.6% (4/15) for TMP-SMZ. No resistance was found to carbapenems (imipenem, meropenem and ertapenem). Conclusion: In our study, it was determined that the most common infectious agent causing urinary tract infection was E. coli. In our study, it was determined that the resistance rates for ciprofloxacin and TMP-SMZ, which are used in empirical treatment, are high, and the resistance rates for fosfomycin and nitrofurantoin are low in E. coli strains that cause urinary system infection. Due to the low rates of resistance in the empirical treatment of urinary system infections, it would be a suitable approach to prefer oral treatment options such as fosfomycin and nitrofurantoin in outpatients.
Read full abstract